Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that  P. David Mozley, M.D. has been appointed as vice president of imaging.  Dr. Mozley will provide medical and scientific leadership across Endocyte's companion imaging agent portfolio.

"We are excited to welcome  Dr. Mozley to our team. He brings a wealth of industry and academic experience in developing novel imaging radiopharmaceuticals and will play a key role at Endocyte as we continue to develop and advance our SMDCs and companion imaging agents," said  Ron Ellis, president and chief executive officer of Endocyte.

"I am thrilled to be joining the Endocyte team. We share a commitment to the development of molecular imaging as an ideal modality for patient selection in clinical trials and a tool for practicing physicians to determine how to best treat patients," said  Dr. Mozley. "Endocyte's SMDC platform and companion imaging agents epitomize the next frontier in molecular imaging and personalized therapies, and I am greatly looking forward to helping advance and expand Endocyte's pioneering work."

Dr. Mozley has over 25 years of experience using radiopharmaceuticals to diagnose and treat diseases. He is a board-certified physician in nuclear medicine. Prior to joining Endocyte, he served as professor and chief of the Division of Nuclear Medicine at Weill Cornell Medical College and the New York Presbyterian Hospital/Weill Cornell Campus in Manhattan. From 2001 to 2012,  Dr. Mozley held multiple positions with progressively increasing responsibilities at Eli Lilly and Merck & Co. While at Merck & Co., he served as senior imaging lead across therapeutic areas for multi-center trials that used imaging as a major endpoint, chaired the PhRMA Imaging group, and co-chaired a technical committee on quantitative imaging for the Radiological Society of North America. He has contributed to the publication of over 100 research reports in the literature on imaging.

Dr. Mozley received his B.S. at the College of William & MaryWilliamsburg, VA, his M.D. from the Brody School of Medicine at East Carolina University, and trained at the University ofPennsylvania in Philadelphia(Original Source)

Shares of Endocyte closed today at $5.98, down $0.10 or 1.73%. ECYT has a 1-year high of $22.89 and a 1-year low of $5.01. The stock's 50-day moving average is $6.08 and it's 200-day moving average is $6.01.

On the ratings front, Endocyte has been the subject of a number of recent research reports. In a report issued on March 3, Wedbush analyst David Nierengarten reiterated a Buy rating on ECYT, with a price target of $12, which implies an upside of 96.7% from current levels. Separately, on March 2, Cantor Fitzgerald's Daniel Brims reiterated a Buy rating on the stock and has a price target of $21.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, David Nierengarten and Daniel Brims have a total average return of 43.3% and -1.9% respectively. Nierengarten has a success rate of 61.3% and is ranked #25 out of 3568 analysts, while Brims has a success rate of 35.7% and is ranked #2921.

Endocyte Inc is a biopharmaceutical company. The Company is engaged in developing targeted therapies for the treatment of cancer and inflammatory diseases.